Cargando…

Impaired 1,25 dihydroxyvitamin D(3) action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH

Osteocytes remodel the perilacunar matrix and canaliculi. X-linked hypophosphatemia (XLH) is characterized by elevated serum levels of fibroblast growth factor 23 (FGF23), leading to decreased 1,25 dihydroxyvitamin D(3) (1,25D) production and hypophosphatemia. Bones from mice with XLH (Hyp) have enl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Ye, Jagga, Supriya, Martins, Janaina S., Rana, Rakshya, Pajevic, Paola Divieti, Liu, Eva S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158930/ https://www.ncbi.nlm.nih.gov/pubmed/34043707 http://dx.doi.org/10.1371/journal.pone.0252348

Ejemplares similares

Impaired 1,25-dihydroxyvitamin D(3) action underlies enthesopathy development in the Hyp mouse model of X-linked hypophosphatemia
por: Rana, Rakshya, et al.
Publicado: (2023)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-Linked Hypophosphatemia (XLH)
por: Ross, Ryan, et al.
Publicado: (2023)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
por: Carpenter, Kelsey A., et al.
Publicado: (2023)

Assessment of the human bone lacuno-canalicular network at the nanoscale and impact of spatial resolution
por: Yu, Boliang, et al.
Publicado: (2020)

X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
por: Takase, Ryosuke, et al.
Publicado: (2020)

SUN-363 Hypophosphatemia Gene Panel Sponsored Program: A High Yield Of Molecular Diagnoses from Clinically Confirmed XLH and Suspected XLH/ Genetic Hypophosphatemia
por: Miller, Nicole, et al.
Publicado: (2020)

Third harmonic generation imaging and analysis of the effect of low gravity on the lacuno-canalicular network of mouse bone
por: Genthial, Rachel, et al.
Publicado: (2019)

Image analysis pipeline for segmentation of a biological porosity network, the lacuno-canalicular system in stingray tesserae
por: Schotte, Merlind, et al.
Publicado: (2020)

Contributions of Resin Cast Etching to Visualising the Osteocyte Lacuno-Canalicular Network Architecture in Bone Biology and Tissue Engineering
por: Sato, Mari, et al.
Publicado: (2023)

Talbot-defocus multiscan tomography using the synchrotron X-ray microscope to study the lacuno-canalicular network in mouse bone
por: Nango, Nobuhito, et al.
Publicado: (2013)

Ptychographic X-ray CT characterization of the osteocyte lacuno-canalicular network in a male rat's glucocorticoid induced osteoporosis model
por: Ciani, Antonia, et al.
Publicado: (2018)

Detailing the influence of PEO-coated biodegradable Mg-based implants on the lacuno-canalicular network in sheep bone: A pilot study
por: Espiritu, Jonathan, et al.
Publicado: (2023)

Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Dahir, Kathryn, et al.
Publicado: (2021)

Abnormal lacuno-canalicular network and negative correlation between serum osteocalcin and Cobb angle indicate abnormal osteocyte function in adolescent idiopathic scoliosis
por: Chen, Huanxiong, et al.
Publicado: (2019)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)
por: Glorieux, Francis H., et al.
Publicado: (2022)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

OR13-3 Hypophosphatemia Gene Panel Sponsored Program: A High Yield of Molecular Diagnoses from Clinically Confirmed XLH and Suspected Genetic Hypophosphatemia
por: Japalaghi, Omid K, et al.
Publicado: (2022)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
por: Ariceta, Gema, et al.
Publicado: (2023)

Kbus/Idr, a mutant mouse strain with skeletal abnormalities and hypophosphatemia: Identification as an allele of 'Hyp'
por: Moriyama, Kenji, et al.
Publicado: (2011)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study
por: Mindler, Gabriel T., et al.
Publicado: (2022)

Biomechanical Impact of Phosphate Wasting on Articular Cartilage Using the Murine Hyp Model of X‐linked hypophosphatemia
por: Macica, Carolyn M, et al.
Publicado: (2023)

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
por: Goto, Shunsuke, et al.
Publicado: (2016)

Novel PHEX gene locus‐specific database: Comprehensive characterization of vast number of variants associated with X‐linked hypophosphatemia (XLH)
por: Sarafrazi, Soodabeh, et al.
Publicado: (2021)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

Recent Progress in Osteocyte Research
por: Divieti Pajevic, Paola
Publicado: (2013)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

THU233 Reduction Of Overutilization Of 1,25-Dihydroxyvitamin D
por: Brown, Jeremy, et al.
Publicado: (2023)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

Outcomes of canalicular trephination versus canaliculodacryocystorhinostomy in common canalicular blocks
por: Vukkadala, Tejaswini, et al.
Publicado: (2022)

Complex formation constant of ferric ion with Gly, Pro-Hyp and Gly-Pro-Hyp
por: Zhi, Mingyu, et al.
Publicado: (2018)

Serum 1,25-Dihydroxyvitamin D: An Outcome Prognosticator in Human Sepsis
por: Nguyen, H. Bryant, et al.
Publicado: (2013)

Focus on 1,25-Dihydroxyvitamin D3 in the Peripheral Nervous System
por: Faye, Pierre Antoine, et al.
Publicado: (2019)

Glucocorticoids cause mandibular bone fragility and suppress osteocyte perilacunar-canalicular remodeling
por: Alemi, A. Sean, et al.
Publicado: (2018)

The ankle in XLH: Reduced motion, power and quality of life
por: Akta, Celine, et al.
Publicado: (2023)

MON-374 Management of 1,25-dihydroxyvitamin D (1,25-OHD) Mediated Hypercalcemia of Unknown Etiology
por: Menon, Sruthi, et al.
Publicado: (2020)

Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3
por: Halicka, H. Dorota, et al.
Publicado: (2012)

The relationship of 1,25-dihydroxyvitamin D and Vitamin D binding protein in periodontitis
por: Rafique, Sara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6d4i5tgbci05dr5j01puo4lu54